SANTA MONICA, Calif., April 9 /PRNewswire-FirstCall/ -- Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said that its international partner, a.bourkas Co., United, Greece, has established a sales operation, and completed their first sale in Germany.
"Europe is starting to look more closely at the collection and storage of umbilical cord blood, which contains stem cells that could be useful for treatment of diabetes, heart disease and other illnesses that are currently impossible to cure," said Matthew Schissler, Cord Blood America Founder and CEO.
"We have been in a partnership in Greece since 2006 and we are very encouraged by their efforts to bring this life saving process to other nations on the European continent," Mr. Schissler said. "We see this as a new, potentially very profitable frontier and we are pleased to be among the leaders in this effort. We are committed to expansion and growth."
About Cord Blood America
Cord Blood America (OTC Bulletin Board: CBAI - News) is the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectant parents and their children. Its mission is to be the most respected stem cell preservation company in the industry. Collected through a safe and non-invasive process, cord blood stem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI - News), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.
CONTACT: Paul Knopick E & E Communications 949/707-5365 pknopick@eandecommunications.com
